Skip to content

FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes

FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes

Today, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.

“Given the challenges many patients experience in achieving their target blood sugar goals, today’s approval of Mounjaro is an important advance in the treatment of type 2 diabetes,” said Patrick Archdeacon, M.D., associate director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research.

Type 2 diabetes, the most common form of diabetes, is a chronic and progressive condition in which the body does not make or use insulin normally, leading to high levels of glucose (sugar) in the blood. More than 30 million Americans have type 2 diabetes. Despite the availability of many medications to treat diabetes, many patients do not achieve the recommended blood sugar goals.

Related Content

Uprising Numbers in Type 2 Diabetes Recent research suggests that...
In a recent development, the World Health Organization’s (WHO) cancer...
Adults with an elevated level of pancreatic fat have higher risk for...
Many COVID-19 patients newly diagnosed with diabetes during hospital admission...
Diabetes is a chronic condition where the body does not...

Talk to Us Now

Learn How to Reverse Diabetes and Pre-Diabetes